About InVivoSIM anti-human NGF (Tanezumab Biosimilar) This non-therapeutic biosimilar antibody uses the same variable regions from the therapeutic antibody Tanezumab making it ideal for research use. This Tanezumab biosimilar reacts with human nerve growth factor (NGF), a neurotrophic factor involved in the regulation of growth, maintenance, proliferation, and survival of certain neurons. NGF is essential for the development and phenotypic maintenance of neurons in the peripheral nervous system (PNS) and for the functional integrity of cholinergic neurons in the central nervous system (CNS). Tanezumab was developed against nerve growth factor as a treatment for pain via a novel mechanisms different from conventional pain-killer drugs. InVivoSIM anti-human NGF (Tanezumab Biosimilar) Specifications IsotypeHuman IgG2, κ Recommended Isotype Control(s)InVivoPlus human IgG2 isotype control Recommended Dilution BufferInVivoPure pH 7.0 Dilution Buffer ImmunogenHuman NGF Reported ApplicationsNGF neutralizationELISA FormulationPBS, pH 7.0 Contains no stabilizers or preservatives Endotoxin<1EU/mg (<0.001EU/μg) Determined by LAL gel clotting assay Aggregation<5% Determined by SEC Purity>95% Determined by SDS-PAGE Sterility0.2 μm filtration PurificationProtein A RRIDAB_2927533 Molecular Weight150 kDa StorageThe antibody solution should be stored at the stock concentration at 4°C. Do not freeze.
